1. What Is the Dengue Vaccine Market?
The Dengue Vaccine Market covers the prophylactic vaccines targeting the dengue virus serotypes DENV-1, DENV-2, DENV-3, and DENV-4 that together cause the 390 million dengue infections annually. The disease is transmitted by the Aedes aegypti mosquito vector across 120 countries. Prior exposure to one dengue serotype increases the risk of severe dengue haemorrhagic fever upon subsequent infection with a different serotype through the antibody-dependent enhancement mechanism that has complicated dengue vaccine development. Dengue vaccines must address the four-serotype coverage requirement and the enhancement risk that the original dengue vaccine controversy demonstrated when the vaccine increased the severe dengue risk in seronegative recipients. Seronegative individuals who received their first dengue antigenic experience through vaccination rather than natural infection had increased severe dengue risk, requiring pre-vaccination serological testing to identify dengue-naive individuals who should not receive the vaccine. The dengue vaccine market is being reshaped by the newer dengue vaccine's clinical data showing protection in seronegative recipients that the original vaccine lacked. This enables the mass vaccination strategy without pre-screening in endemic settings where the operational complexity and cost of pre-vaccination serology testing limited the original dengue vaccine programme.
2. Dengue Vaccine Market Size & Forecast
3. Emerging Technologies
- Dengvaxia seroprevalence pre-screening requirement following the Philippines safety signal that showed increased severe dengue hospitalisation in seronegative vaccinated individuals has made the serological pre-screening the mandatory gating test that limits Dengvaxia use. Countries and populations with the high seroprevalence that makes the number of seronegative individuals who receive the vaccine small enough to manage the enhanced disease risk are the target for the Dengvaxia programme. The pre-screening requirement adds the operational cost and complexity that has limited the scale of the Dengvaxia vaccination programme.
- Takeda Qdenga TDV chimeric tetravalent live attenuated dengue vaccine uses the attenuated DENV-2 backbone with the envelope and pre-membrane genes of DENV-1, DENV-3, and DENV-4 inserted. The Phase III TIDES trial demonstrated protection across all four serotypes including the seronegative population, enabling the broader vaccination strategy that does not require pre-vaccination serological testing. The seronegative efficacy data is the defining clinical advantage that the Qdenga label has over the Dengvaxia label in the mass vaccination setting.
- Mass vaccination campaign targeting the 9 to 16 year school-age population in high-seroprevalence dengue endemic settings uses the two-dose schedule that national immunisation programmes in Indonesia, Brazil, and Latin America are implementing. The programmatic vaccination approach achieves the population coverage that reduces dengue transmission in the endemic countries where the disease burden is highest. School-based delivery provides the access to the target age group that routine clinic-based vaccination cannot reach at equivalent coverage.
- Dengue rapid diagnostic test integration with the vaccination programme identifies the dengue-naive individuals who should defer vaccination with serotype-dependent vaccines and stratifies the severe dengue risk in the vaccinated population. Seroprevalence screening is the programme implementation requirement that mass vaccination strategy must address for the vaccines where the serostatus affects the risk-benefit calculation. Point-of-care dengue serology tests are being developed to enable the rapid pre-vaccination screening that the dengue vaccination programme requires.
Such innovations are driving change across adjacent industries too. Discover more in our Flu Vaccine Market.
4. Key Market Opportunity
Substantial growth potential in the Dengue Vaccine market comes from national immunisation programme adoption, where endemic country government decisions to include Qdenga in their childhood or adolescent vaccination schedules create the volume procurement that defines commercial success. Manufacturers securing NIP tenders across high-burden endemic markets capture this volume. Another growth driver centers on travel vaccine demand expanding with global mobility. As NIP adoption grows and climate-driven endemic area expansion proceeds, the addressable opportunity is growing from limited seropositive-restricted vaccination toward broader endemic population coverage.
5. Top Companies in the Dengue Vaccine Market
The following organisations hold leading positions in the Dengue Vaccine Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Sanofi
- Takeda
- Bharat Biotech
- Merck
- Serum Institute of India
- Panacea Biotec
- Instituto Butantan
6. Market Segmentation
The Dengue Vaccine Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Product | Dengvaxia Qdenga Pipeline |
| By Age Group | Paediatric Adolescent Adult |
| By Programme | Endemic Country NIP Travel |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Dengue Vaccine Market trajectory over the forecast period:
Takeda Qdenga Demonstrating Protection in Seronegative Recipients Without Enhanced Disease Risk Unlike Dengvaxia Has Enabled the Mass Dengue Vaccination Strategy Without Mandatory Pre-Vaccination Serological Screening That Dengvaxia Required.Takeda's Qdenga national immunisation programme launch in Indonesia targeting 6-9 year olds at highest dengue burden is the largest Qdenga deployment to date, establishing the pricing model for national dengue vaccine programmes at approximately USD 20-25 per dose in middle-income markets that differs from GAVI-supported low-income country purchasing requiring below USD 5 per dose. Brazil's national dengue vaccination programme launched in 2024 using Qdenga in municipalities with highest incidence demonstrated the flexibility of school-based programme implementation that public health infrastructure from HPV vaccine delivery had established across Latin America. The seroprevalence data from endemic countries establishing that 60-80% of school-age children have prior dengue infection supports the seropositive-unrestricted Qdenga indication in populations where most vaccine recipients have pre-existing dengue immunity that the vaccine boosts.
Qdenga School-Age Mass Vaccination Campaigns in Indonesia, Brazil, and Latin America Using Two-Dose Schedule Without Pre-Screening Are Implementing the Population Coverage Strategy That Makes Dengue Prevention a Public Health Programme Rather Than a Screened Individual Decision.World Mosquito Program's city-wide Wolbachia mosquito release in Medellín Colombia achieved 97% reduction in dengue incidence in intervention neighbourhoods within 2 years, demonstrating environmental biological control can achieve transmission blocking rates exceeding current vaccine efficacy at population level. Novel insecticide formulations including Sumitomo Chemical's indoxacarb targeting pyrethroid-resistant Aedes aegypti are deployed in dengue-endemic cities where insecticide resistance has reduced conventional vector control, and the WHOPES recommendation process for novel public health insecticides creates regulatory pathways analogous to the vaccine approval pathway. The dengue prevention strategy integration question of optimising vaccination combined with Wolbachia biological control and novel insecticide deployment is being addressed through mathematical modelling at WHO and national public health agencies.
Dengvaxia Seroprevalence Pre-Screening Requirement Following Philippines Safety Signal Has Made Serological Testing the Mandatory Gate That Limits Dengvaxia to Seropositive Recipients Where Enhanced Disease Risk for Seronegative Individuals Is Avoided.Merck's V180 recombinant dengue E antigen, NIH's tetravalent live-attenuated DENVax-based platform, and Panacea's Indian manufacturing approach represent the next wave of dengue vaccine development aiming for improved efficacy, simpler administration schedules, and lower manufacturing costs enabling lower-income country national dengue vaccination programmes. The regulatory success of Qdenga with seropositive-unrestricted indication has established a target profile for second-generation dengue vaccines, and the SEARCH FOR PRIME dengue immunological correlates of protection consortium is identifying antibody and T-cell parameters predicting efficacy, enabling Phase 2 immunogenicity endpoints predicting Phase 3 clinical efficacy without multi-year placebo-controlled outcome trials. The DENVax-based candidates benefit from the clinical safety and immunogenicity track record of related live-attenuated chimeric dengue backbone technology used in the Qdenga programme.
For related market intelligence, see the Vaccine Market.
8. Segmental Analysis
By product, the Qdenga segment dominated the Dengue Vaccine Market in 2025, as Takeda's tetravalent live-attenuated vaccine achieved regulatory approval across multiple endemic markets and started large-scale immunisation in the Philippines and Brazil, generating the leading share of commercial dengue vaccine revenue.
By age group, the school-age and paediatric segment is projected to register the highest growth rate through 2034, as national dengue vaccination programmes across Southeast Asia and Latin America prioritise the highest-burden child population for serotype-independent protection.
9. Regional Analysis
Regional demand patterns across the Dengue Vaccine Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
Latin America dominated the Dengue Vaccine Market in 2025, accounting for approximately 12% of global revenue, due to the highest dengue burden countries in Brazil, Colombia, and Argentina and the early adoption of Dengvaxia in national programmes before the safety concerns and Qdenga's initial Latin American approvals. Moreover, Brazil's large endemic population and dengue outbreak frequency sustain vaccination demand. In addition, the Instituto Butantan is developing a domestic dengue vaccine for the Brazilian market. Regional leadership is attributed to this combination of endemic burden and early programme experience.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Dengue Vaccine Market through 2034, driven by national immunisation programme adoption in Indonesia, Philippines, Thailand, and India with Qdenga and the large populations at risk creating substantial vaccination volumes. The region is also witnessing government procurement programmes evaluating dengue vaccine inclusion. Moreover, the high dengue burden sustains public health investment in vaccination. The combination of these demand drivers and NIP adoption positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Dengue Vaccine Market was valued at USD 452.40 Mn in 2025 and is projected to reach USD 1,788.40 Mn by 2034, growing at a CAGR of 16.5% over the 2026–2034 forecast period.
The Dengue Vaccine Market is projected to grow at a CAGR of 16.5% from 2026 to 2034.
Latin America dominated the Dengue Vaccine Market in 2025, accounting for approximately 12% of global revenue, due to the highest dengue burden countries in Brazil, Colombia, and Argentina and the early adoption of Dengvaxia in national programmes before the safety concerns and Qdenga's initial Latin American approvals.
The leading companies in the Dengue Vaccine Market include Sanofi, Takeda, Bharat Biotech, Merck, Serum Institute of India, Panacea Biotec, Instituto Butantan.
Takeda qdenga demonstrating protection in seronegative recipients without enhanced disease risk unlike dengvaxia has enabled the mass dengue vaccination strategy without mandatory pre-vaccination serological screening that dengvaxia required.
By product, the Qdenga segment dominated the Dengue Vaccine Market in 2025, as Takeda's tetravalent live-attenuated vaccine achieved regulatory approval across multiple endemic markets and started large-scale immunisation in the Philippines and Brazil, generating the leading share of commercial dengue vaccine revenue.
How to Order
Choose Your Package
Who competes in this market, how large each player is, and where they sit against each other.
- Business overview, HQ, headcount & ownership
- Product and brand portfolio mapped per company
- Recent developments: launches, M&A, partnerships, capacity
- SWOT and strategic posture for each player
- 2025 market share split by company, plus “others”
- Company revenue mapping in USD Mn
- Competitive landscape matrix & quadrant positioning
- Concentration read: top-5 share and fragmentation
The forecast model itself. Every table from the study as clean, formula-ready Excel across 3 segmentation axes. Choose how much geography you need.
- One country, broken out across 3 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 3 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack (Package 2.3)
- Complete research methodology, assumptions & appendix
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.